SOURCE-LINKED STUDY SUMMARY
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
Abstract summarizedQuality not appraised
- What was studied
- Clinical guideline covering prevention, diagnosis and treatment of fatty liver disease linked to metabolic risk factors.
- Who / model studied
- The guidance addresses adults with metabolic fatty liver disease, including people with type 2 diabetes or obesity.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- The guideline advises lifestyle changes and management of coexisting diabetes or obesity, including semaglutide or tirzepatide when indicated. It discusses resmetirom for adults with non-cirrhotic liver inflammation and significant scarring, subject to local approval.
- Limitations & context
- The guideline states that no disease-targeted drug could then be recommended for the cirrhotic stage.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/j.jhep.2024.04.031